ADC Therapeutics SA annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
ADC Therapeutics SA R&D Spending Growth & History (ADCT)
ADC Therapeutics SA's r&d spending was $104.0M for fiscal 2025.
View full ADC Therapeutics SA company overviewADC Therapeutics SA annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $104.0M | −$5.6M | −5.13% |
| 2024 | 2024-12-31 | $109.6M | −$17.5M | −13.76% |
| 2023 | 2023-12-31 | $127.1M | −$60.8M | −32.34% |
| 2022 | 2022-12-31 | $187.9M | $29.9M | +18.92% |
| 2021 | 2021-12-31 | $158.0M | $16.0M | +11.24% |
| 2020 | 2020-12-31 | $142.0M | $34.5M | +32.08% |
| 2019 | 2019-12-31 | $107.5M | −$10.8M | −9.11% |
| 2018 | 2018-12-31 | $118.3M | — | — |
ADC Therapeutics SA quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $17.4M | −$12.7M | −42.29% |
| Q1 2026 | 2026-03-31 | $19.9M | −$9.1M | −31.29% |
| Q4 2025 | 2025-12-31 | $18.2M | −$8.9M | −32.90% |
| Q3 2025 | 2025-09-30 | $26.8M | −$5.7M | −17.53% |
| Q2 2025 | 2025-06-30 | $30.1M | $5.8M | +23.85% |
| Q1 2025 | 2025-03-31 | $28.9M | $3.2M | +12.41% |
| Q4 2024 | 2024-12-31 | $27.1M | −$162,000 | −0.59% |
| Q3 2024 | 2024-09-30 | $32.5M | $4.1M | +14.28% |
| Q2 2024 | 2024-06-30 | $24.3M | −$7.6M | −23.95% |
| Q1 2024 | 2024-03-31 | $25.7M | −$13.7M | −34.82% |
| Q4 2023 | 2023-12-31 | $27.3M | −$21.5M | −44.06% |
| Q3 2023 | 2023-09-30 | $28.4M | −$13.2M | −31.76% |
| Q2 2023 | 2023-06-30 | $31.9M | −$16.6M | −34.19% |
| Q1 2023 | 2023-03-31 | $39.5M | −$9.5M | −19.35% |
| Q4 2022 | 2022-12-31 | $48.7M | $6.2M | +14.69% |
| Q3 2022 | 2022-09-30 | $41.7M | $4.9M | +13.23% |
| Q2 2022 | 2022-06-30 | $48.5M | $9.0M | +22.78% |
| Q1 2022 | 2022-03-31 | $49.0M | $9.8M | +24.97% |
| Q4 2021 | 2021-12-31 | $42.5M | −$6.1M | −12.48% |
| Q3 2021 | 2021-09-30 | $36.8M | $4.7M | +14.46% |
| Q2 2021 | 2021-06-30 | $39.5M | $13.6M | +52.34% |
| Q1 2021 | 2021-03-31 | $39.2M | $3.8M | +10.73% |
| Q4 2020 | 2020-12-31 | $48.6M | — | — |
| Q3 2020 | 2020-09-30 | $32.2M | — | — |
| Q2 2020 | 2020-06-30 | $25.9M | — | — |
| Q1 2020 | 2020-03-31 | $35.4M | — | — |
ADC Therapeutics SA r&d spending trends
Over the last five fiscal years, ADC Therapeutics SA's r&d spending decreased from $142.0M to $104.0M, a change of −$38.0M. The latest reported quarter, Q2 2026, shows $17.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ADC Therapeutics SA source filings ↗